Annexon, Inc.

NASDAQ:ANNX

Biotechnology

Healthcare
$3.52 -0.71%

-$0.04 today

Market cap
$576.73M
Beta
1.18
P/E (TTM)
-4.8
EPS (TTM)
-$1.01
52W Low $1.85High $7.18

Volume 2.98M

Average 2.56M

ANNX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Annexon, Inc.NASDAQ: ANNX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$957K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$1.9M.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$957K or moves back toward the trailing-twelve-month quarterly average of -$475.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$957K-1.3% QoQ
Last fiscal yearDec 2025
-$3.69M-6.7% YoY
LTMMar 2026
-$1.9M— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-6.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(3.69M) USD
Year-over-year change
-6.7%

Gross Profit vs competitors

How ANNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
ANNX Competitors
Gross Profit for ANNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$270.54M USD+582.2%—116.4%
QTTBQ32 Bio Inc.LTM Mar 2026$53.38M USD+14926.4%+100.2%99.3%
XNCRXencor, Inc.LTM Jun 2026$45.46M USD-54.8%—43.3%
PRTAProthena Corporation plcLTM Mar 2026$27.14M USD-80.3%-51.9%46.8%
IMVTImmunovant, Inc.LTM Sep 2026$7.1M USD——100.0%
ALMSAlumis Inc. Common StockLTM Jun 2026$6.53M USD-66.1%—88.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$6.39M USD+74.8%-31.4%76.3%
ACIUAC Immune S.A.LTM Mar 2026CHF 3.7M CHF-86.9%-3.2%100.0%
ABVXAbivax S.A.FY2025€0 EUR———
ANNXAnnexon, Inc.LTM Mar 2026-$1.9M USD———
IFRXInflaRx N.V.LTM Mar 2026-€7.23M EUR-142.9%—24646.3%
Peer median (excluding ANNX) —-60.4%-17.3%99.3%

Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0003.45M3.69M
Gross Profit000(3.45M)(3.69M)
Gross Margin—————
Research & Development100.07M112.5M113.76M119.45M184.7M
Selling, General & Admin30.65M30.95M28.02M34.63M31.71M
Operating Expenses130.71M145.6M143.72M150.62M212.72M
Depreciation & Amortization2.14M2.15M2.15M3.45M2.65M
EBITDA(128.18M)(139.8M)(132.09M)(134.75M)(204.04M)
EBITDA Margin—————
Operating Income(130.71M)(145.6M)(143.72M)(154.07M)(216.41M)
Operating Margin—————
Interest Income390K3.65M9.49M15.87M9.72M
Interest Expense00000
Other Income / Expenses390K3.65M9.49M15.87M9.72M
Income Before Tax(130.32M)(141.95M)(134.24M)(138.2M)(206.69M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(130.32M)(141.95M)(134.24M)(138.2M)(206.69M)
Net Margin—————
EPS (Basic)(3.34)(2.60)(1.77)(1.01)(1.34)
EPS (Diluted)(3.34)(2.60)(1.77)(1.01)(1.34)
Weighted Avg Shares38.32M54.67M75.67M137.4M155.11M
Weighted Avg Shares (Diluted)38.32M54.67M75.67M137.4M155.11M

Annexon, Inc.

NASDAQ:ANNX

Intrinsic Alpha fair value

Locked

Current Price

$3.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.